{"id":"zegerid","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL1503","moleculeType":"Small molecule","molecularWeight":"345.42"},"aliases":["omeprazole/sodium bicarbonate, SCH 900934"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$106.0718/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$38,716","description":"ZEGERID 40 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Zegerid","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:05:53.087317+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:05:57.819782+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zegerid","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:05:58.307069+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Potassium-transporting ATPase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:05:59.438105+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1503/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:05:59.022925+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"1d764fc5-8eae-4fc9-a2e9-3f1954a3ac05","title":"ZEGERID OTC (OMEPRAZOLE, SODIUM BICARBONATE) CAPSULE [RILEY CONSUMER CARE LLC]"},"ecosystem":[],"_scrapedAt":"2026-03-28T00:16:27.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:06:00.721111+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00001337","phase":"PHASE2","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-05-08","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma","enrollment":348},{"nctId":"NCT00978016","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2009-09","conditions":"Gastroesophageal Reflux Disease","enrollment":460},{"nctId":"NCT00045799","phase":"PHASE3","title":"Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2002-05","conditions":"Upper Gastrointestinal Bleeding","enrollment":354},{"nctId":"NCT03100838","phase":"PHASE1","title":"Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-03-20","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT02922933","phase":"PHASE1","title":"A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2016-10-25","conditions":"Volunteers, Healthy Volunteers, Human Volunteers","enrollment":66},{"nctId":"NCT03491995","phase":"PHASE3","title":"A Unique Regimen for Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-04-01","conditions":"Helicobacter Infections","enrollment":600},{"nctId":"NCT01661101","phase":"PHASE3","title":"Management of Myocardial Injury After Noncardiac Surgery Trial","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2013-01","conditions":"Myocardial Injury After Noncardiac Surgery (MINS)","enrollment":1754},{"nctId":"NCT01129778","phase":"NA","title":"Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus","status":"TERMINATED","sponsor":"Stanford University","startDate":"2009-11","conditions":"Barrett Esophagus, Gastroesophageal Reflux","enrollment":27},{"nctId":"NCT00557349","phase":"PHASE4","title":"Ulcer Prevention Study in Post Gastric Bypass Patients","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2006-11","conditions":"Marginal Ulcers","enrollment":40},{"nctId":"NCT00808769","phase":"PHASE4","title":"Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2008-11","conditions":"Normal Healthy Subject Population","enrollment":30},{"nctId":"NCT00765206","phase":"PHASE3","title":"A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-05","conditions":"Gastric Acid, Human Experimentation","enrollment":60},{"nctId":"NCT01005719","phase":"PHASE3","title":"Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-09","conditions":"Human Experimentation","enrollment":63},{"nctId":"NCT00674115","phase":"PHASE3","title":"A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Gastric Acid, Human Experimentation","enrollment":60},{"nctId":"NCT01587885","phase":"PHASE4","title":"Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-01","conditions":"Heartburn","enrollment":48},{"nctId":"NCT01077076","phase":"PHASE3","title":"Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Intragastric Acidity","enrollment":30},{"nctId":"NCT01337804","phase":"PHASE1","title":"A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01","conditions":"Heartburn","enrollment":50},{"nctId":"NCT01493089","phase":"PHASE3","title":"Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Norgine","startDate":"2011-04","conditions":"Gastroesophageal Reflux","enrollment":239},{"nctId":"NCT01710995","phase":"PHASE1","title":"A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Norgine","startDate":"2010-10","conditions":"Acid Reflux, Gastro Oesophageal Reflux Disease","enrollment":20},{"nctId":"NCT00693225","phase":"PHASE4","title":"Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study","status":"COMPLETED","sponsor":"Yvonne Romero","startDate":"2008-01","conditions":"Erosive Esophagitis","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL1503"},"formularyStatus":[],"_approvalHistory":[{"date":"20240205","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA201361"},{"date":"20240205","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA201361"},{"date":"20240205","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA201361"},{"date":"20240205","type":"SUPPL","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA201361"},{"date":"20160715","type":"ORIG","sponsor":"PERRIGO R AND D","applicationNumber":"ANDA201361"},{"date":"20060227","type":"ORIG","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20120419","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20220304","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20111207","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20210316","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20100903","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20190924","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20071221","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20160601","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20140225","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20121109","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20110520","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20201127","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20100120","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20180607","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20230718","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20161024","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20141219","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021849"},{"date":"20131115","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20251125","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20110725","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20221213","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20101220","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20100415","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20221101","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20171030","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20160421","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20091201","type":"ORIG","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20150610","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20120918","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20230424","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20101220","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20190115","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20170217","type":"SUPPL","sponsor":"RILEY CONSUMER","applicationNumber":"NDA022281"},{"date":"20180607","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20230718","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20161024","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20100903","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20140225","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20120419","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20040615","type":"ORIG","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20111207","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20220304","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20141219","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20201127","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20100120","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20131220","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20190924","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20121109","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"},{"date":"20110520","type":"SUPPL","sponsor":"SALIX","applicationNumber":"NDA021636"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":10,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Zegerid","genericName":"Zegerid","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:06:00.721111+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}